Palliative resection followed by concurrent chemoradiotherapy and targeted therapy resulted in an overall survival of 23 months in a patient with primary cardiac angiosarcoma.
Case Report (n=1)
Does palliative resection followed by chemoradiotherapy and targeted therapy improve survival in a patient with primary cardiac angiosarcoma?
A multidisciplinary approach including palliative resection, chemoradiotherapy, and targeted therapy with anlotinib achieved an overall survival of 23 months in a patient with primary cardiac angiosarcoma.
Primary cardiac angiosarcoma is relatively rare, and most cases involve metastasis at the time of diagnosis. The median survival time is 14 months for patients who can be treated surgically, versus 3.8 ± 2.5 months for patients with metastasis who could not undergo surgery. Radical surgical resection, radiotherapy, chemotherapy, and targeted therapy are the main treatments, but prognosis remains poor because of rapid progression and high recurrence and metastasis rates. At present, there is no unified standard treatment, and selecting the correct treatment plan and improving patient survival and quality of life remain challenging. We have reported the case of a 45-year-old woman with a primary heart tumor that infiltrated the right atrial wall and pericardium. Angiosarcoma was verified histologically. After palliative resection of the primary tumor followed by concurrent chemoradiotherapy and targeted therapy, the patient exhibited overall survival of 23 months, highlighting the potential utility of this treatment strategy.
Fang et al. (Sun,) conducted a case report in Primary cardiac angiosarcoma (n=1). Palliative resection followed by concurrent chemoradiotherapy and targeted therapy was evaluated on Overall survival. Palliative resection followed by concurrent chemoradiotherapy and targeted therapy resulted in an overall survival of 23 months in a patient with primary cardiac angiosarcoma.